Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Reuters, Fierce Pharma and NBC News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 10h ago.
Quick answers
Why is "Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer Bloomberg.com · 1d ago
- Amgen drug combined with immunotherapy extends survival in lung cancer trial Reuters · 1d ago
- ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer Fierce Pharma · 1d ago
- ‘Practice-changing’ new lung cancer immunotherapy improves survival NBC News · 1d ago
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen · 1d ago
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer CNBC · 1d ago
Topics
Related trends
How to prevent osteoporosis, from training to eating calcium-rich food
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
U.S. stocks tumble as crude oil approaches $100 per barrel and inflation data approaches.
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.